Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy.

ABSTRACT: Effective treatment of established tumors requires rational multicombination immunotherapy strategies designed to target all functions of the patient immune system and tumor immune microenvironment. While these combinations build on the foundation of successful immune checkpoint blockade antibodies, it is increasingly apparent that successful immunotherapy will also require a cancer vaccine backbone to engage the immune system, thereby ensuring that additional immuno-oncology agents will engage a tumor-specific immune response. This review summarizes ongoing clinical trials built upon the backbone of cancer vaccines and focusing on those clinical trials that utilize multicombination (3+) immuno-oncology agents. We examine combining cancer vaccines with multiple checkpoint blockade antibodi

SUBMITTER: Wolfson B 

PROVIDER: S-EPMC8156017 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature